vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Tecnoglass Inc. (TGLS). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $245.3M, roughly 1.2× Tecnoglass Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 10.6%, a 85.7% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 2.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 12.8%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Tecnoglass Inc. is a leading manufacturer of high-performance architectural glass, aluminum windows, doors, and associated building components. It primarily caters to residential and commercial construction sectors across North America and Latin America, offering custom, energy-efficient solutions for new construction and renovation projects.
ACAD vs TGLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $245.3M |
| Net Profit | $273.6M | $26.1M |
| Gross Margin | 90.8% | 40.0% |
| Operating Margin | 6.1% | 18.3% |
| Net Margin | 96.3% | 10.6% |
| Revenue YoY | 9.4% | 2.4% |
| Net Profit YoY | 90.3% | -44.5% |
| EPS (diluted) | $1.61 | $0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $245.3M | ||
| Q3 25 | $278.6M | $260.5M | ||
| Q2 25 | $264.6M | $255.5M | ||
| Q1 25 | $244.3M | $222.3M | ||
| Q4 24 | $259.6M | $239.6M | ||
| Q3 24 | $250.4M | $238.3M | ||
| Q2 24 | $242.0M | $219.7M | ||
| Q1 24 | $205.8M | $192.6M |
| Q4 25 | $273.6M | $26.1M | ||
| Q3 25 | $71.8M | $47.2M | ||
| Q2 25 | $26.7M | $44.1M | ||
| Q1 25 | $19.0M | $42.2M | ||
| Q4 24 | $143.7M | $47.0M | ||
| Q3 24 | $32.8M | $49.5M | ||
| Q2 24 | $33.4M | $35.0M | ||
| Q1 24 | $16.6M | $29.7M |
| Q4 25 | 90.8% | 40.0% | ||
| Q3 25 | 92.2% | 42.7% | ||
| Q2 25 | 92.2% | 44.7% | ||
| Q1 25 | 91.7% | 43.9% | ||
| Q4 24 | 91.6% | 44.5% | ||
| Q3 24 | 92.5% | 45.8% | ||
| Q2 24 | 92.5% | 40.8% | ||
| Q1 24 | 88.8% | 38.8% |
| Q4 25 | 6.1% | 18.3% | ||
| Q3 25 | 12.8% | 25.1% | ||
| Q2 25 | 12.2% | 24.0% | ||
| Q1 25 | 7.9% | 26.7% | ||
| Q4 24 | 59.1% | 28.0% | ||
| Q3 24 | 12.6% | 28.4% | ||
| Q2 24 | 12.6% | 23.3% | ||
| Q1 24 | 7.4% | 21.3% |
| Q4 25 | 96.3% | 10.6% | ||
| Q3 25 | 25.8% | 18.1% | ||
| Q2 25 | 10.1% | 17.3% | ||
| Q1 25 | 7.8% | 19.0% | ||
| Q4 24 | 55.4% | 19.6% | ||
| Q3 24 | 13.1% | 20.8% | ||
| Q2 24 | 13.8% | 15.9% | ||
| Q1 24 | 8.0% | 15.4% |
| Q4 25 | $1.61 | $0.57 | ||
| Q3 25 | $0.42 | $1.01 | ||
| Q2 25 | $0.16 | $0.94 | ||
| Q1 25 | $0.11 | $0.90 | ||
| Q4 24 | $0.86 | $1.00 | ||
| Q3 24 | $0.20 | $1.05 | ||
| Q2 24 | $0.20 | $0.75 | ||
| Q1 24 | $0.10 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $104.1M |
| Total DebtLower is stronger | — | $174.4M |
| Stockholders' EquityBook value | $1.2B | $713.1M |
| Total Assets | $1.6B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $104.1M | ||
| Q3 25 | $258.0M | $127.1M | ||
| Q2 25 | $253.6M | $140.9M | ||
| Q1 25 | $217.7M | $160.2M | ||
| Q4 24 | $319.6M | $137.5M | ||
| Q3 24 | $155.1M | $124.8M | ||
| Q2 24 | $177.1M | $129.5M | ||
| Q1 24 | $204.7M | $138.8M |
| Q4 25 | — | $174.4M | ||
| Q3 25 | — | $114.7M | ||
| Q2 25 | — | $110.6M | ||
| Q1 25 | — | $110.6M | ||
| Q4 24 | — | $111.1M | ||
| Q3 24 | — | $126.8M | ||
| Q2 24 | — | $144.7M | ||
| Q1 24 | — | $160.9M |
| Q4 25 | $1.2B | $713.1M | ||
| Q3 25 | $917.3M | $764.0M | ||
| Q2 25 | $822.4M | $736.0M | ||
| Q1 25 | $765.2M | $685.1M | ||
| Q4 24 | $732.8M | $631.2M | ||
| Q3 24 | $577.2M | $613.3M | ||
| Q2 24 | $516.7M | $574.8M | ||
| Q1 24 | $464.0M | $573.6M |
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.2B | $1.0B | ||
| Q3 24 | $976.9M | $996.3M | ||
| Q2 24 | $914.1M | $942.5M | ||
| Q1 24 | $855.1M | $981.6M |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.25× | ||
| Q1 24 | — | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $31.0M |
| Free Cash FlowOCF − Capex | — | $11.4M |
| FCF MarginFCF / Revenue | — | 4.7% |
| Capex IntensityCapex / Revenue | — | 8.0% |
| Cash ConversionOCF / Net Profit | -0.18× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $31.0M | ||
| Q3 25 | $74.3M | $40.0M | ||
| Q2 25 | $64.0M | $17.9M | ||
| Q1 25 | $20.3M | $46.9M | ||
| Q4 24 | $40.4M | $61.1M | ||
| Q3 24 | $63.2M | $41.5M | ||
| Q2 24 | $25.0M | $34.5M | ||
| Q1 24 | $29.1M | $33.4M |
| Q4 25 | — | $11.4M | ||
| Q3 25 | $73.9M | $21.2M | ||
| Q2 25 | — | $-14.7M | ||
| Q1 25 | — | $16.5M | ||
| Q4 24 | — | $35.4M | ||
| Q3 24 | $63.2M | $17.8M | ||
| Q2 24 | — | $14.2M | ||
| Q1 24 | — | $23.6M |
| Q4 25 | — | 4.7% | ||
| Q3 25 | 26.5% | 8.2% | ||
| Q2 25 | — | -5.7% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 14.8% | ||
| Q3 24 | 25.2% | 7.5% | ||
| Q2 24 | — | 6.5% | ||
| Q1 24 | — | 12.2% |
| Q4 25 | — | 8.0% | ||
| Q3 25 | 0.1% | 7.2% | ||
| Q2 25 | — | 12.7% | ||
| Q1 25 | — | 13.7% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | 0.0% | 9.9% | ||
| Q2 24 | — | 9.2% | ||
| Q1 24 | — | 5.1% |
| Q4 25 | -0.18× | 1.19× | ||
| Q3 25 | 1.03× | 0.85× | ||
| Q2 25 | 2.40× | 0.41× | ||
| Q1 25 | 1.07× | 1.11× | ||
| Q4 24 | 0.28× | 1.30× | ||
| Q3 24 | 1.93× | 0.84× | ||
| Q2 24 | 0.75× | 0.98× | ||
| Q1 24 | 1.76× | 1.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
